{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T13:46:52Z","timestamp":1781012812975,"version":"3.54.1"},"reference-count":22,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Heart Journal"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.ahj.2025.05.004","type":"journal-article","created":{"date-parts":[[2025,5,22]],"date-time":"2025-05-22T19:11:57Z","timestamp":1747941117000},"page":"105-116","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Structural abnormalities and effects of sacubitril\/valsartan in patients with mildly reduced or preserved ejection fraction and worsening heart failure: The PARAGLIDE-HF trial"],"prefix":"10.1016","volume":"289","author":[{"given":"Veraprapas","family":"Kittipibul","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derek D.","family":"Cyr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josephine","family":"Harrington","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anuradha","family":"Lala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marat","family":"Fudim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan H.","family":"Ward","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samiha","family":"Sarwat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott D.","family":"Solomon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian F.","family":"Hernandez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shelley","family":"Zieroth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Randall C.","family":"Starling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert J.","family":"Mentz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ahj.2025.05.004_bib0001","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1001\/jama.2023.2020","article-title":"Heart failure with preserved ejection fraction: a review","volume":"329","author":"Redfield","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.ahj.2025.05.004_bib0002","doi-asserted-by":"crossref","first-page":"3297","DOI":"10.1093\/eurheartj\/ehz641","article-title":"How to diagnose heart failure with preserved ejection fraction: the HFA-PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC)","volume":"40","author":"Pieske","year":"2019","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ahj.2025.05.004_bib0003","doi-asserted-by":"crossref","first-page":"2491","DOI":"10.1161\/CIRCULATIONAHA.110.011031","article-title":"Prevalence and significance of alterations in cardiac structure and function in patients with heart failure and a preserved ejection fraction","volume":"124","author":"Zile","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2025.05.004_bib0004","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1093\/cvr\/cvaa228","article-title":"Heart failure with preserved ejection fraction: insights into diagnosis and pathophysiology","volume":"117","author":"Nagueh","year":"2021","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.ahj.2025.05.004_bib0005","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jacc.2023.04.019","article-title":"Angiotensin-neprilysin inhibition in patients with mildly reduced or preserved ejection fraction and worsening heart failure","volume":"82","author":"Mentz","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2025.05.004_bib0006","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1016\/j.cardfail.2023.02.001","article-title":"Rationale, design and baseline characteristics of the PARAGLIDE-HF trial: Sacubitril\/Valsartan vs Valsartan in HFmrEF and HFpEF with a worsening heart failure event","volume":"29","author":"Mentz","year":"2023","journal-title":"J Card Fail"},{"key":"10.1016\/j.ahj.2025.05.004_bib0007","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1056\/NEJMoa1908655","article-title":"Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction","volume":"381","author":"Solomon","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2025.05.004_bib0008","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1056\/NEJMoa2206286","article-title":"Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction","volume":"387","author":"Solomon","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2025.05.004_bib0009","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1111\/1467-9868.00259","article-title":"Semiparametric regression for the mean and rate functions of recurrent events","volume":"62","author":"Lin","year":"2000","journal-title":"J Royal Stat Soc Series B (Stat Methodol)"},{"key":"10.1016\/j.ahj.2025.05.004_bib0010","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1016\/j.jacc.2023.03.393","article-title":"2023 ACC expert consensus decision pathway on management of heart failure with preserved ejection fraction: a report of the american college of cardiology solution set oversight committee","volume":"81","author":"Kittleson","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2025.05.004_bib0011","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.jacc.2006.08.050","article-title":"Cardiovascular features of heart failure with preserved ejection fraction versus nonfailing hypertensive left ventricular hypertrophy in the urban Baltimore community: the role of atrial remodeling\/dysfunction","volume":"49","author":"Melenovsky","year":"2007","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2025.05.004_bib0012","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1002\/ejhf.2805","article-title":"Left atrial enlargement is associated with pulmonary vascular disease in heart failure with preserved ejection fraction","volume":"25","author":"Gard","year":"2023","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.ahj.2025.05.004_bib0013","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1161\/CIRCHEARTFAILURE.114.001667","article-title":"Left atrial remodeling and function in advanced heart failure with preserved or reduced ejection fraction","volume":"8","author":"Melenovsky","year":"2015","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.ahj.2025.05.004_bib0014","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1152\/japplphysiol.00374.2015","article-title":"Myocardial hypertrophy and its role in heart failure with preserved ejection fraction","volume":"119","author":"Heinzel","year":"2015","journal-title":"J Appl Physiol (1985)"},{"key":"10.1016\/j.ahj.2025.05.004_bib0015","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1016\/j.jacc.2024.01.027","article-title":"Sacubitril\/valsartan in patients hospitalized with decompensated heart failure","volume":"83","author":"Morrow","year":"2024","journal-title":"J Am College Cardiol"},{"key":"10.1016\/j.ahj.2025.05.004_bib0016","doi-asserted-by":"crossref","first-page":"3029","DOI":"10.1016\/j.jacc.2017.04.043","article-title":"Hospitalization for recently diagnosed versus worsening chronic heart failure: from the ASCEND-HF trial","volume":"69","author":"Greene","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2025.05.004_bib0017","doi-asserted-by":"crossref","DOI":"10.1016\/j.jacadv.2024.100984","article-title":"Effects of sacubitril\/valsartan vs valsartan in de novo vs acute on chronic HFpEF and HFmrEF","volume":"3","author":"Murray","year":"2024","journal-title":"JACC Adv"},{"key":"10.1016\/j.ahj.2025.05.004_bib0018","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1016\/j.cardfail.2024.04.030","article-title":"Association of sacubitril\/valsartan vs valsartan with blood pressure changes and symptomatic hypotension: the PARAGLIDE-HF Trial","volume":"30","author":"Fudim","year":"2024","journal-title":"J Card Fail"},{"key":"10.1016\/j.ahj.2025.05.004_bib0019","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1038\/s41569-022-00705-w","article-title":"The need for increased pragmatism in cardiovascular clinical trials","volume":"19","author":"Usman","year":"2022","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.ahj.2025.05.004_bib0020","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1093\/eurheartj\/ehab798","article-title":"Effect of empagliflozin in patients with heart failure across the spectrum of left ventricular ejection fraction","volume":"43","author":"Butler","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ahj.2025.05.004_bib0021","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.jacc.2024.05.005","article-title":"Cardiovascular-Kidney-Metabolic Overlap in Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Trial-Level Analysis","volume":"84","author":"Ostrominski","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2025.05.004_bib0022","doi-asserted-by":"crossref","DOI":"10.1016\/j.echo.2014.10.003","article-title":"Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging","volume":"28","author":"Lang","year":"2015","journal-title":"J Am Soc Echocardiogr"}],"container-title":["American Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870325001619?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870325001619?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T04:57:13Z","timestamp":1767761833000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002870325001619"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":22,"alternative-id":["S0002870325001619"],"URL":"https:\/\/doi.org\/10.1016\/j.ahj.2025.05.004","relation":{},"ISSN":["0002-8703"],"issn-type":[{"value":"0002-8703","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Structural abnormalities and effects of sacubitril\/valsartan in patients with mildly reduced or preserved ejection fraction and worsening heart failure: The PARAGLIDE-HF trial","name":"articletitle","label":"Article Title"},{"value":"American Heart Journal","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ahj.2025.05.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}